Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05947708 · ClinicalTrials.gov registry record · NA
The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300
A NA study of End Stage Renal Disease on Dialysis, sponsored by Outset Medical.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT05947708: Completed NA study of End Stage Renal Disease on Dialysis, sponsored by Outset Medical.
NCT05947708 is a NA study of End Stage Renal Disease on Dialysis that has completed, run by Outset Medical. The registered enrollment target is 41 participants, below the 73-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05947708, a NA study of End Stage Renal Disease on Dialysis, has completed, sponsored by Outset Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.
Primary Outcome
Adequacy (as determined by Kt/V of 1.2 or greater) of patients treated with chronic (3x/wk), dialysis or who have a recovery time of more than 4 hours, when treated on a Tablo hemodialysis device versus conventional, i.e. non Tablo, hemodialysis device.
Conditions Studied
Interventions
- DEVICE Dialysate Flow Rate
Study Locations (1)
California
- Outset Medical - San Jose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-09-15 |
| Est. Completion | 2020-01-15 |
| Phase | NA |
What the finished NCT05947708 record still lists
NCT05947708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 73-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (44% lower).
The record links to 1 condition, with End Stage Renal Disease on Dialysis appearing as the primary indexed condition, and to 1 intervention - of which Dialysate Flow Rate is the first listed.
NCT05947708 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05947708 about?
NCT05947708 is a clinical study titled "The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300". Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.
What is the current status of trial NCT05947708?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2019-09-15. Estimated completion is 2020-01-15.
What conditions does trial NCT05947708 study?
This clinical trial studies the following conditions: End Stage Renal Disease on Dialysis.
What interventions are being tested in trial NCT05947708?
The interventions under investigation include: Dialysate Flow Rate (DEVICE).
Who is sponsoring clinical trial NCT05947708?
This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05947708 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease on Dialysis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05947708's enrollment target sits among peer trials
41 5th of 9 higher than 5 of 9 other End Stage Renal Disease on Dialysis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease on Dialysis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
RECRUITING · NA
-
Comparing Surgical and Endovascular Arteriovenous Fistula Creation
RECRUITING · NA
-
The Home Blood Pressure (BP) Trial
ACTIVE NOT RECRUITING · NA
-
MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence
ACTIVE NOT RECRUITING · NA
-
Motivational Strategies To Empower African Americans To Improve Dialysis Adherence
COMPLETED · NA
-
First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI